Harnessing innovation to protect lives in Africa and beyond.
Why Vaccine Technology Matters
At LunaVax, we believe life-saving science should be accessible to everyone, everywhere. That’s why we develop next-generation vaccine platforms that are faster to produce, easier to scale, and designed to meet the unique health needs of communities across Africa.
These innovations aren’t just about science—they’re how we close the global vaccine equity gap and create a healthier future for all.
The Technologies We Use
1. mRNA Vaccines
mRNA vaccines teach the body to make proteins that trigger an immune response. They are fast to develop, highly adaptable, and ideal for responding to emerging threats.
- Targeted Diseases: HPV, measles, malaria, past applications in COVID-19, and future outbreak-prone infections.
- Why We Use Them: Rapid development, precision targeting, and strong efficacy.
2. Viral Vector Vaccines
These vaccines use a harmless virus to deliver genetic material, stimulating immunity. They are durable and effective, especially in resource-limited settings.
- Targeted Diseases: Tuberculosis, malaria, measles, and other candidates for future applications..
- Why We Use Them: Proven platforms with strong immune activation.
3. DNA-Based Vaccines
DNA vaccines are stable, easy to store, and can be produced locally without complex infrastructure.
- Targeted Diseases: Hepatitis B, HPV, and potential applications in future emerging infections.
- Why We Use Them: Heat-stable, scalable, and cost-effective—perfect for rural areas.
4. Protein Subunit Vaccines
These vaccines use harmless pieces of the pathogen to build immunity.
- Targeted Diseases: Meningitis, pneumonia, and polio.
- Why We Use Them: Safe for children and immunocompromised patients.
How We Make Them
Our mission extends beyond research. We are building a resilient ecosystem for vaccine development through:
- Local production facilities
- Technology transfer partnerships
- Regional supply chain development
- Sustainable manufacturing training
Why It Matters for Africa
- 90% of vaccines used in Africa are imported, making supply chains fragile.
- Only 5% of African nations have full-cycle vaccine production.
- LunaVax is changing that by tailoring technologies to fit Africa’s needs—building local resilience and empowering communities.
Join the Innovation
Together, we can accelerate access to life-saving vaccines across Africa.
Whether you’re a biotech innovator, funding organization, government agency, or academic partner—we welcome collaborators who believe in equitable healthcare solutions.
Explore Partnership Opportunities or Contact Us to shape the future of immunization.